Compare AbbVie Inc (ABBV) vs PubMatic Inc (PUBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs PubMatic Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while PubMatic Inc trades at $13.09 (market cap $619.32M). The key difference: AbbVie Inc is far larger — about 726.5× PubMatic Inc's market cap, and AbbVie Inc pays a 2.72% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| ABBV | PUBM | |
|---|---|---|
Market Cap | $449.91B | $619.32M |
Sector | Health | Technology |
52-Week High | $261.07 | $13.83 |
52-Week Low | $184.85 | $6.28 |
Enterprise Value | $513.38B | $516.83M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
PubMatic trades at $13.32, down 1.7% over 24 hours, with a bullish technical signal from moving averages and a consensus price target of $17. The company reported a net loss of $14.46M in 2025 despite revenue of $282.93M, though it has beaten earnings expectations in recent quarters. Recent news highlights partnerships and product launches, such as the Creator Marketplace and AgenticOS integrations, aimed at driving growth in digital advertising.
The outlook is mixed: analyst sentiment is evenly split between Buy and Hold, with potential upside to the price target, but profitability concerns and a high P/E ratio of 132 pose risks. Investors should weigh the company's innovation in AI-driven ad tech against ongoing losses and competitive pressures in the programmatic advertising space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
